T 1712/17 (Pharmaceutical Formulations Containing Methylnaltrexone / PROGENICS) of 22.09.2020
- European Case Law Identifier
- ECLI:EP:BA:2020:T171217.20200922
- Date of decision
- 22 September 2020
- Case number
- T 1712/17
- Petition for review of
- -
- Application number
- 04759349.6
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- PHARMACEUTICAL FORMULATIONS CONTAINING METHYLNALTREXONE
- Applicant name
- PROGENICS PHARMACEUTICALS, INC.
- Opponent name
- Actavis Group PTC ehf
Fresenius Kabi Deutschland GmbH - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2) (2007)European Patent Convention Art 84 (2007)Rules of procedure of the Boards of Appeal Art 11 (2020)Rules of procedure of the Boards of Appeal Art 12(4) (2007)
- Keywords
- Late-filed request - request identical to request not admitted in first instance proceedings
Late-filed request - admitted (yes)
Amendments - extension beyond the content of the application as filed (no)
Remittal to the department of first instance - special reasons for remitting the case - Catchword
- -
- Cited cases
- T 1966/16
- Citing cases
- -
Order
For these reasons it is decided that:
The decision under appeal is set aside.
The case is remitted to the opposition division for further prosecution.